Atrial fibrillation (AF) is the most frequent cardiac arrhythmia, which is associated
with an enhanced risk for stroke and myocardial infarction [
1
,
2
,
3
]. Vitamin K antagonists (VKAs) have been the golden standard for stroke prophylaxis
but they are associated with a significant risk of bleeding [
[4]
]. VKAs are unsuitable for many patients, due to difficulties related to the frequent
need for check of INR values, or to difficulties in achieving and maintaining an adequate
Time in Therapeutic Range (TTR). Non-vitamin K oral anticoagulants (NOACs), inhibiting
activated Factor X or prothrombin, represent a valid alternative, as they showed similar
efficacy to VKAs with a safer profile [
- Lip G.Y.
- Andreotti F.
- Fauchier L.
- Huber K.
- Hylek E.
- Knight E.
- et al.
Bleeding risk assessment and management in atrial fibrillation patients: a position
document from the European Heart Rhythm Association, endorsed by the European Society
of Cardiology Working Group on Thrombosis.
Europace. 2011; 13: 723-746
[5]
], without the need for frequent laboratory monitoring [
6
,
7
].- Camm A.J.
- Lip G.Y.
- De Caterina R.
- Savelieva I.
- Atar D.
- Hohnloser S.H.
- et al.
2012 Focused update of the ESC Guidelines for the management of atrial fibrillation:
an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed
with the special contribution of the European Heart Rhythm Association.
Eur Heart J. 2012; 33: 2719-2747
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Incidence of myocardial infarction and vascular death in anticoagulated elderly patients with atrial fibrillation: Relation to atherosclerotic risk factors.Chest. 2015; 147: 1644-1650
- Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.Circulation. 1998; 98: 946-952
- Atrial fibrillation and the risk of myocardial infarction.JAMA Int Med. 2014; 174: 107-114
- Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.Europace. 2011; 13: 723-746
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.Lancet. 2014; 383: 955-962
- European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Europace. 2013; 15: 625-651
- 2012 Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.Eur Heart J. 2012; 33: 2719-2747
- Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients.J Thromb Haemost. 2011; 106: 968-977
- Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.PLoS One. 2013; 8: e63479
- Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF).Europace. 2014; 16: 6-14
Article info
Publication history
Published online: June 26, 2015
Accepted:
June 15,
2015
Received:
June 10,
2015
Identification
Copyright
© 2015 Published by Elsevier Inc.